By Kao Shih-ching / Staff reporterPharmaceutical company SynCore Biotechnology Co Ltd (杏國新藥) yesterday said that it plans to begin a phase III clinical trial of its new pancreatic cancer drug SB05PC in China, after gaining the approval of the Chinese regulator last month. As the company has completed a phase II trial for SB05PC in the US, the Chinese National Medical Products Administration (NMPA) approved the phase III trial, a company official surnamed Liang (梁) told the Taipei Times by telephone yesterday. SynCore has applied for SB05PC to be a first-line treatment in China, Liang said. Meanwhile, the company’s global phase III clinical trial in seven other nations — Taiwan, the US, France, Hungary, South Korea, Russia and Israel — is progressing smoothly, he said. Based on the results of the phase II trial, the company said it is confident that the phase III trial will meet its primary efficacy endpoint and improve the rates of survival of enrolled patients.

Source: Taipei Times July 05, 2019 15:56 UTC